


The AlzheimerGuard logo icon consists of a stylized, semi-circular arrangement of vertical bars in blue, orange, and purple, similar in style to the T-NeuroDx logo.

AlzheimerGuard™

*Built from the Biology that Drives Alzheimer's
Not the Pathology it Leaves Behind*

The Cost of Alzheimer's Disease to US Healthcare is Enormous

Most common dementia affecting
7 million
people in the US


\$384 Billion
in total **annual** US medical & long-term care
costs

>99%
of Alzheimer's drug trials **fail**

Biomarkers measure pathology
not disease

The Problem:

Today's Alzheimer's Biomarkers Detect Pathology Not Disease




Biomarkers able to identify who will get disease before symptoms are desperately needed

The Solution:

T-Neuro's AlzheimerGuard Biomarker Opens the Door to Early Detection *An Age-Related Immune Cell that Causes Alzheimer's Pathology*

Disease Detection Can Start Here!




The AlzheimerGuard blood test detects Alzheimer's Disease, not just its pathology

The Science:


T-Neuro's "hiT Cells"

A Type of Age-Related CD8 Memory T Cells Induce Alzheimer's Pathology


Causes Pathology in Normal Mice - Mechanistic



Strong Disease Signal in Human Blood



Groundbreaking Publication




"The study.....could thus represent a paradigm shift."

An early Alzheimer's disease signal associated with disease mechanism

Amyloid-Tau-Neurodegeneration (ATN) Panels Define the Market

Existing tests detect pathology NOT disease



T-Neuro's hiT Cells are uniquely positioned to drive Alzheimer's Dx earlier


The Product:

A Simple Blood Test to Detect Alzheimer's Early

Global Access



Freedom to Operate: Exclusive global commercial license with rights to sub-license



A Capital Efficient Asset

Investors: Minimal infrastructure & staffing needs - Made by CDMOs, validated by CROs.

Customers: No specialized equipment needed - Runs on existing lab equipment



Blood Draw



Send to Lab



Perform Test



Global Clinical Instrumentation Footprint



Run on Standard Flow Cytometers

A standard assay kit run with standard clinical technology established worldwide

The Market Opportunity

Blood-Based AD Testing is Entering an Explosive Growth Phase

TAM   

All Dx

12% CAGR

2030 -> 2035

2030 TAM
\$4.1B

2030 SAM
\$722M

2035 SOM
\$85M

SAM  

Blood-Based Dx

25% CAGR

2030 -> 2035


 AlzheimerGuard™

SOM  

hiT Cell Assay


2030 FDA Clearance

SAM – Global BB Diagnostics



Population-scale Alzheimer's diagnostics emerging as a reality with blood tests

T-Neuro's Roadmap to Exit



*
RUO = Research Use Only
LDT = Lab Developed Test with Partner Lab

Staged go-to-market: Clinical Trials → Worried Well/Triage → Standard of Care

Traction

Secured NIH Funding and Significant Strategic Partners in 2025

\$500K Phase 1 SBIR Grant



National Institute
on Aging



USC University of
Southern California

T-NeuroDx Secures \$500,000 NIH Grant to Advance Novel
Alzheimer's Disease Blood Biomarker Research

**400 Sample Clinical Data
Expansion**

In progress – first data in April

CLIA Partner – 2027 Launch



TrilliumBio And T-NeuroDx Announce Strategic
Collaboration To Commercialize Blood-Based
Biomarkers For Alzheimer's Disease

**LDT Commercialization
Partner**

Validating ATN Panels

Research Collaboration



Beckman Coulter Life Sciences, T-NeuroDx
Collaborate on Early Alzheimer's Diagnostics

Assay Technology Transfer

Poster at ADPD

NIH support & signed partners are de-risking commercialization

The Team:

Deep, Relevant Expertise to Bring AlzheimerGuard to Market



Michael Reed, PhD
Chief Executive Officer



Chris Wheeler, PhD
Co-Founder
Chief Science Officer



Elena Afonina, PhD
Clinical Product Development
Consultant



Kimberly Klein
Chief Business Officer



John Chavez
Co-Founder
Chief Financial Officer



Wayne Laslie
Chief Operating Officer



Scientific Advisory Board



Jeffrey Cummings, MD



SAB Chair

World-renowned Alzheimer's clinical trialist
Sits on multiple drug trial steering committees



Lawrence Steinman, MD



World-renowned neurodegeneration and
autoimmune disorder researcher & entrepreneur

Recruiting for world-class research neurologist
and biomarker discovery expert advisors

Deep team experience to accelerate market entry

The Ask:

Bridge to Value Inflection for Priced Series A

Jumping Off Point

Proof Points Secured

2026

2027

Use of Funds
Milestones Unlocked



Mechanistic Biomarker



CEDARS-SINAI

Exclusive Global License

Strategic Partnerships



BECKMAN
COULTER
Life Sciences



TRILLIUMBIO



\$1.3M Raised to Date:
\$700K Equity | \$600K Grants



%	Milestone	Date
70%	Biomarker Validation	Q1 27
20%	RUO Kit & LDT Launch	Q2 27
10%	FDA Breakthrough/Pre-Sub	Q4 26
	Reimbursement Strategy	Q1 27

Series A
2030 FDA Clearance



Why Now? De-risking the science and market access creates a clear FDA and payer path in 2027



*Built from the Biology that Drives Alzheimer's
Not the Pathology it Leaves Behind*

Raising:

\$2M pre-Series A SAFE | \$15M Post-money cap

Contact:

Michael Reed, CEO

Email: mreed@tneurodx.com

Phone/WhatsApp: +1-305-301-5357

Book a meeting here: <https://meetings.hubspot.com/mikereed186/mike-30-minute-meeting>